← signals
2026-07-24·ASML·regulatory change
medup

Multiple prediction market questions on Manifold Markets dated July 24, 2026, shed light on ASML's near-term outlook...

Multiple prediction market questions on Manifold Markets dated July 24, 2026, shed light on ASML's near-term outlook and risks.

window 30devidence 11confidence score 71price ASML $1784.87

confidence score

Usable evidence: enough corroboration to publish, with 1 independent source class.

71
medium confidence1 independent source classesmarketmedium high without independent sourcespasses publish gate
priced-in check

ASML has not made a large direction-matching 30-90 day move yet.

not priced in
as of 2026-07-167d n/a45d n/a90d +23%yahoo

signal brief

Multiple prediction market questions on Manifold Markets dated July 24, 2026, shed light on ASML's near-term outlook and risks. The market strongly believes ASML maintains its EUV monopoly: 96.17% chance it is the sole EUV producer by end 2024 (source 9), 79.92% remain only producer until end 2026 (source 1), and 70.76% until end 2027 (source 4). Revenue growth is also highly expected: 83.77% probability of yearly revenue increase for next 5 years (source 3). However, significant risks emerge: 50% chance US forces ASML to halt exports to China before 2029 (source 8) and 43% chance US cuts ASML off from Cymer before 2030 (source 5). Chinese domestic EUV invention is seen as possible: 56.45% by 2030 (source 7). Despite these, China currently does not have an ASML EUV machine (15.65% chance, source 2) and no evidence of sales to China in 2023 (6.28%, source 10). Overall, the market sees ASML's monopoly and revenue as strong, but with mounting regulatory and competitive pressures.

What the sources said

  • Source 9: "YES=96.17%" on ASML monopoly in EUV by end 2024.
  • Source 1: "YES=79.92%" on ASML remaining only EUV producer until end 2026.
  • Source 8: "YES=50.00%" on US forcing halt of China exports before 2029.
  • Source 7: "YES=56.45%" on China inventing domestic EUV by 2030.

source data used

spillover entities

Decision support, not stock advice. This signal is research with cited evidence — not a recommendation to buy, sell, or hold any security.